In our February Lunch-and-Learn webinar, Professor Alastair Greystoke discussed the progress that has been made in adopting circulating tumour DNA (ctDNA) testing across the NHS.
Circulating tumour DNA (ctDNA) testing is a cutting-edge diagnostic technique that involves the detection and analysis of fragmented DNA shed into the bloodstream by cancer cells. This non-invasive method provides valuable insights into the genetic makeup of tumours and allows for the monitoring of cancer progression and treatment response.
Unlike traditional tissue biopsies, ctDNA testing offers a less invasive and more dynamic approach, enabling clinicians to track genetic changes in real-time. CtDNA testing plays a pivotal role in early cancer detection, treatment optimisation, and the identification of potential drug resistance. Its importance lies in its ability to provide a comprehensive understanding of a patient’s cancer at the molecular level, facilitating personalised and targeted therapies for improved treatment outcomes.
Professor Alastair Greystoke is an Honorary Medical Oncologist and North East & Yorkshire Genomic Medicine Service’s Clinical Director (Cancer). He has been leading a project to drive wider adoption of ctDNA testing across the NHS. In this webinar, he discussed the progress that has been made, what we have learned, and what the future may hold in this transformative area of care.
You can watch a record of the webinar below.